Cumberland Pharmaceuticals (CPIX) Total Non-Current Liabilities (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $44.1 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $44.1 million, up 23.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.1 million (up 23.84% YoY), and the FY2025 annual result was $46.5 million, down 0.6% from the prior year.
• Total Non-Current Liabilities came in at $44.1 million for Q1 2026 at Cumberland Pharmaceuticals, down from $46.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $49.4 million in Q4 2022 to a low of $33.9 million in Q2 2025.
• The 5-year median for Total Non-Current Liabilities is $45.6 million (2023), against an average of $43.8 million.
• Across the five-year window, Total Non-Current Liabilities soared 43.64% in 2022 and decreased 26.16% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Total Non-Current Liabilities stood at $49.4 million in 2022, then retreated by 6.69% to $46.1 million in 2023, then grew by 1.47% to $46.7 million in 2024, then declined by 0.6% to $46.5 million in 2025, then dropped by 5.13% to $44.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $44.1 million (Q1 2026), $46.5 million (Q4 2025), and $34.1 million (Q3 2025), per Business Quant data.